AX-2026-042237

SS-31 (Elamipretide) · 50 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2604-D1599

PASSVERIFIED

Report ID: AX-2026-042237
Compound: SS-31 (Elamipretide)
Compound class: Metabolic and mitochondrial peptides
Supplier: Homopeptide — Hunan Aslsen Technology Co., Ltd.
Batch / lot: HOMO-2604-D1599
Declared label claim: 50mg
Laboratory: Janoshik Analytical
Assay date: 09 Jul 2026
Submitted: 27 Jul 2026
Quarter: 2026-Q3
Submitter: am.hartmann
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.93	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — des-Dmt (−193 Da)	0.04	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	639.3856	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	639.3823	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-5.1	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	87.90	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	87.84	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	58.02	mg	50 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	50.965	mg	50 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	101.9	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.12	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	8.20	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.78	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White to pale-yellow cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Visible particulates, did not clear	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.32	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	9.00	min	8.94 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.14	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	69,075	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Arg1]-epimer	1.28	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 69,075, and skew follows the reported asymmetry factor of 1.14. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.04 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	SS-31 (Elamipretide) — main peak	9.00	4,856,908	99.93	—
2	des-Dmt (−193 Da)	8.28	1,944	0.04	-193.110
3	[D-Arg1]-epimer	8.82	1,458	0.03	0.000
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 639.3856 Da, computed from C32H49N9O5. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 639.3823 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	320.7001	320.6984	-0.0017	50.8
1+	640.3929	640.3896	-0.0033	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.12
Counter-ion (acetate)	ion chromatography	8.20
Residual solvent + inorganic residue	estimated	0.78
Total peptide content	by difference	87.90
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.93	divergence +0.13 pp vs batch median
Total impurities (% area)	0.10	0.07
Largest single impurity (% area)	0.07	0.04
Water (%)	0.9	3.12
Counter-ion (%)	5.4	8.20
Peptide content (%w/w)	93.1	87.90
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 6 d) → assay. Submitter did not handle the vial.
Assay date: 09 Jul 2026
Submitted to the index: 27 Jul 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot HOMO-2604-D1599 n=2

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042236	HOMO-2604-D1599	PeptideMeter	2026-Q3	99.61	2.79	—	Supplier-supplied	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent SS-31 (Elamipretide) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042067	TFC	TFC-2604-Y7472	Kestrel	2026-Q3	98.66	4.44	—	Supplier-supplied	1	MARGINAL
AX-2026-042068	TFC	TFC-2604-Y7472	Medutest	2026-Q3	98.71	3.63	92.9	Supplier-supplied	2	MARGINAL
AX-2026-042069	TFC	TFC-2604-Y7472	Janoshik	2026-Q3	98.16	3.65	—	Supplier-supplied	2	FAIL
AX-2026-042070	TFC	TFC-2604-Y7472	PeptideMeter	2026-Q3	98.09	3.60	97.9	Supplier-supplied	1	FAIL
AX-2026-042072	TFC	TFC-2604-Y7472	VendorInvestigate	2026-Q3	97.88	3.47	89.5	Buyer-sourced	2	FAIL
AX-2026-042236	Homopeptide	HOMO-2604-D1599	PeptideMeter	2026-Q3	99.61	2.79	—	Supplier-supplied	0	PASS
AX-2026-041951	TFC	TFC-2607-R4363	Medutest	2026-Q3	99.56	5.16	—	Buyer-sourced	0	PASS
AX-2026-042071	TFC	TFC-2604-Y7472	PeptideMeter	2026-Q3	97.71	3.47	93.0	Laboratory-retained	2	FAIL

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042181	Ipamorelin	HOMO-2608-A9045	Janoshik	2026-Q3	99.78	4.79	—	Supplier-supplied	1	MARGINAL
AX-2026-042172	Semaglutide	HOMO-2604-X8921	Janoshik	2026-Q3	99.64	5.16	91.9	Supplier-supplied	1	MARGINAL
AX-2026-042278	SLU-PP-332	HOMO-2602-Y2822	Kestrel	2026-Q3	99.71	4.42	—	Supplier-supplied	0	PASS
AX-2026-042180	Ipamorelin	HOMO-2608-A9045	Janoshik	2026-Q3	99.39	4.74	105.5	Supplier-supplied	1	MARGINAL
AX-2026-042184	Ipamorelin	HOMO-2608-A9045	Kestrel	2026-Q3	99.27	4.79	103.2	Supplier-supplied	1	MARGINAL
AX-2026-042274	SLU-PP-332	HOMO-2602-Y2822	VendorInvestigate	2026-Q3	98.71	4.72	—	Laboratory-retained	0	PASS
AX-2026-042183	Ipamorelin	HOMO-2608-A9045	VendorInvestigate	2026-Q3	99.38	4.97	—	Buyer-sourced	1	MARGINAL
AX-2026-042194	Retatrutide	HOMO-2605-V9833	PeptideMeter	2026-Q3	98.90	4.07	98.8	Supplier-supplied	3	MARGINAL